Enhanced autophagy reveals vulnerability of P-gp mediated epirubicin resistance in triple negative breast cancer cells

被引:0
作者
Li-han Zhang
Ai-jun Yang
Min Wang
Wei Liu
Chen-yu Wang
Xiao-feng Xie
Xu Chen
Jing-fei Dong
Min Li
机构
[1] Lanzhou University,Institute of Integrated Traditional Chinese and Western Medicine, School of Basic Medical Sciences
[2] Lanzhou University,Institute of Pathology, School of Basic Medical Sciences
[3] BloodWorks Northwest Research Institute,Division of Hematology, Department of Medicine
[4] University of Washington,Key Laboratory of Preclinical Study for New Drugs of Gansu Province
[5] School of Medicine,undefined
[6] Lanzhou University,undefined
来源
Apoptosis | 2016年 / 21卷
关键词
Autophagy; P-gp; NF-κB; Epirubicin; Chemotherapy resistance; Triple negative breast cancer;
D O I
暂无
中图分类号
学科分类号
摘要
Epirubicin (EPI) is widely used for triple negative breast cancer (TNBC), but a substantial number of patients develop EPI resistance that is associated with poor outcome. The underlying mechanism for EPI resistance remains poorly understood. We have developed and characterized an EPI-resistant (EPI-R) cell line from parental MDA-MB-231 cells. These EPI-R cells reached stable growth in the medium containing 8 μg/ml of EPI. They overexpressed P-glycoprotein (P-gp) and contained numerous autophagic vacuoles. The suppression of P-gp overexpression and/or autophagy restored the sensitivity of these EPI-R cells to EPI. We further show that autophagy conferred resistance to EPI on MDA cells by blocking the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)-mediated pro-apoptotic signals. Together, these results reveal a synergistic role of P-gp, autophagy, and NF-κB pathways in the development of EPI resistance in TNBC cells. They also suggest that blocking the P-gp overexpression and autophagy may be an effective means of reducing EPI resistance.
引用
收藏
页码:473 / 488
页数:15
相关论文
共 209 条
[1]  
Foulkes WD(2010)Triple-negative breast cancer N Engl J Med 363 1938-1948
[2]  
Smith IE(2011)Molecular heterogeneity of triple-negative breast cancer and its clinical implications Curr Opin Oncol 23 566-577
[3]  
Reis-Filho JS(2010)Directed therapy of subtypes of triple-negative breast cancer Oncologist 15 49-56
[4]  
Irshad S(2012)Dissecting the heterogeneity of triple-negative breast cancer J Clin Oncol 30 1879-1887
[5]  
Ellis P(2013)Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer Exp Oncol 35 287-290
[6]  
Tutt A(2013)MDR-1 and GST polymorphisms are involved in myelodysplasia progression Leuk Res 37 970-973
[7]  
Carey LA(2012)Prognostic evaluation of CapG, gelsolin, P-gp, GSTP1, and Topo-II proteins in non-small cell lung cancer Anat Rec 295 208-214
[8]  
Metzger-Filho O(2014)DNA repair pathways in trypanosomatids: from DNA repair to drug resistance Microbiol Mol Biol Rev 78 40-73
[9]  
Tutt A(2010)Modulation of mitochondrial permeability transition pore affects multidrug resistance in human hepatocellular carcinoma cells Int J Biol Sci 6 773-783
[10]  
de Azambuja E(2014)In vitro modulation of P-glycoprotein, MRP-1 and BCRP expression by mangiferin in doxorubicin-treated MCF-7 cells Asian Pac J Cancer Prev 15 1639-1642